{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:50:31Z","timestamp":1765547431521,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.msard.2025.106554","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T19:26:25Z","timestamp":1748546785000},"page":"106554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Fingolimod in multiple sclerosis: insights into drug survival and discontinuation factors"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7721-2093","authenticated-orcid":false,"given":"Ana Beatriz","family":"Simon-Nogueira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur Cesario","family":"de Holanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael Augusto","family":"Rosalem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thiago Ivan Vilchez","family":"Santillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateus Boaventura","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira Luisa","family":"Ap\u00f3stolos-Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarso","family":"Adoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dagoberto","family":"Callegaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme Diogo","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2025.106554_bib0001","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.clinthera.2015.03.001","article-title":"New FDA-approved disease-modifying therapies for multiple sclerosis","volume":"37","author":"English","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.msard.2025.106554_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.637107","article-title":"Descriptive analysis of real-world data on fingolimod long-term treatment of young adult RRMS patients","volume":"12","author":"Ziemssen","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106554_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286419878324","article-title":"Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results","volume":"12","author":"Cohen","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106554_bib0004","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.msard.2025.106554_bib0005","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1177\/1352458517703193","article-title":"No evident disease activity\": the use of combined assessments in the management of patients with multiple sclerosis","volume":"23","author":"Giovannoni","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106554_bib0006","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jns.2018.03.018","article-title":"Real-world persistence with fingolimod for the treatment of multiple sclerosis: a systematic review and meta-analysis","volume":"388","author":"Kantor","year":"2018","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106554_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.637107","article-title":"Descriptive analysis of real-world data on fingolimod long-term treatment of young adult RRMS patients","volume":"12","author":"Ziemssen","year":"2021","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106554_bib0008","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1007\/s00415-021-10931-w","article-title":"PANGAEA study group. Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany","volume":"269","author":"Ziemssen","year":"2022","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.msard.2025.106554_bib0009","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3109\/00207454.2014.969839","article-title":"Experience with fingolimod in clinical practice","volume":"125","author":"Hersh","year":"2014","journal-title":"Int. J. Neurosci."},{"issue":"4","key":"10.1016\/j.msard.2025.106554_bib0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176174","article-title":"The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: an observational study","volume":"12","author":"Izquierdo","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2025.106554_bib0011","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/jnnp.2008.145805","article-title":"Relapses in multiple sclerosis are age- and time-dependentJournal of Neurology","volume":"79","author":"Tremlett","year":"2008","journal-title":"Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106554_bib0012","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11910-020-01046-2","article-title":"Impact of age on multiple sclerosis disease activity and progression","volume":"20","author":"Zeydan","year":"2020","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.msard.2025.106554_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.799138","article-title":"Evolution of disease modifying therapy benefits and risks: an argument for de-escalation as a treatment paradigm for patients with multiple sclerosis","volume":"12","author":"Vollmer","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106554_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577721","article-title":"Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: a systematic review and meta-analysis","volume":"360","author":"Sriwastava","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106554_bib0015","first-page":"261","article-title":"Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations","volume":"12","author":"Ayzenberg","year":"2016","journal-title":"Ther. Clin. Risk Manag."},{"issue":"11","key":"10.1016\/j.msard.2025.106554_bib0016","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1590\/0004-282x-anp-2021-0162","volume":"79","author":"Becker","year":"2021","journal-title":"Arq. Neuropsiquiatr."},{"issue":"2","key":"10.1016\/j.msard.2025.106554_bib0017","first-page":"341","article-title":"SARS-CoV-2 mRNA vaccination in people with multiple sclerosis treated with fingolimod: protective humoral immune responses may develop after the preferred third shot","volume":"10","author":"Achtnichts","year":"2022","journal-title":"Vacc. (Basel)"},{"issue":"5 Suppl 1","key":"10.1016\/j.msard.2025.106554_bib0018","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1590\/0004-282x-anp-2022-s121","article-title":"Challenges and insights in immunization in patients with demyelinating diseases: a bench-to-bedside and evidence-based review","volume":"80","author":"Silva","year":"2022","journal-title":"Arq. Neuropsiquiatr."},{"key":"10.1016\/j.msard.2025.106554_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.04.004","article-title":"TEMPORARY REMOVAL: immunization and multiple sclerosis: recommendations from the French Multiple Sclerosis Society","author":"Lebrun","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"13","key":"10.1016\/j.msard.2025.106554_bib0020","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1212\/WNL.0000000000008157","article-title":"Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"93","author":"Farez","year":"2019","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.msard.2025.106554_bib0021","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","article-title":"Varicella-Zoster Virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management","volume":"72","author":"Arvin","year":"2015","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.msard.2025.106554_bib0022","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1177\/1352458521991433","article-title":"Human papillomavirus lesions in 16 MS patients treated with fingolimod: outcomes and vaccination","volume":"27","author":"Mhanna","year":"2021","journal-title":"Multip. Sclero. J."},{"issue":"8","key":"10.1016\/j.msard.2025.106554_bib0023","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40263-021-00842-9","article-title":"The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: a narrative review","volume":"35","author":"Biolato","year":"2021","journal-title":"CNS Drug."},{"issue":"3","key":"10.1016\/j.msard.2025.106554_bib0024","first-page":"773","article-title":"Pregnancy and family planning in multiple sclerosis","volume":"25","author":"Langer-Gould","year":"2019","journal-title":"Continuum (Minneap. Minn.)"},{"issue":"8","key":"10.1016\/j.msard.2025.106554_bib0025","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.0000000000000137","article-title":"Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis","volume":"82","author":"Karlsson","year":"2014","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:41:54Z","timestamp":1755650514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825002962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":25,"alternative-id":["S2211034825002962"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106554","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fingolimod in multiple sclerosis: insights into drug survival and discontinuation factors","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106554"}}